Alimta 100mg/500mg Inj

Product Details:

Generic Content-Pemetrexed, Manufactured By: Dr.Reddy’s Lab,India

Pemgem is approved by the FDA for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. Pemgem is not indicated for patients who have a different type of NSCLC called squamous cell.

Available As: 100 Mg & 500 Mg.

Product Details:

We are engaged in offering Alimta, which is used in combination with cisplatin for treatment of metastatic nonsquamous non-small cell lung cancer. Our range is prescribed for the patients, whose disease has not progressed after 4 cycles of platinum-based 1st-line chemotherapy or as a single agent after prior chemotherapy. We offer these products in customized packaging and at cost effective prices to our valued clients.

Other Information

• Pay Mode Terms: L/C (Letter of Credit), D/A (Documents against Acceptance), D/P (Documents against Payment), T/T (Bank Transfer), Western Union, Other

Product Details:

This Drug is used in Solid Tumors but mainly used in Lung Cancer. 

Dosage Forms are : 
1)100 Mg Vial for Injection
2)500 Mg Vial for Injection

Product Details:

Generic Content-Pemetrexed, Manufactured By:Eli Lilly,France

Alimta is approved for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, to maintain the effect of initial treatment with chemotherapy.

Available As: 100 Mg Injection & 500 Mg Injection

Additional Information:

• Pay Mode Terms: L/C (Letter of Credit),T/T (Bank Transfer),Other

Product Details:

ALIMTA^® (pemetrexed for injection) is approved by the FDA in combination with (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC. ALIMTA is not indicated for patients who have different type of NSCLC called squamous cell.

To Maintain the Effect of Initial Chemotherapy Before Worsening of Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer

ALIMTA is approved by the FDA for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

If Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer Returns

ALIMTA is approved by the FDA as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, after prior chemotherapy. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

Treatment for Malignant Pleural Mesothelioma

ALIMTA is a treatment for malignant pleural mesothelioma (MPM), which is a cancer that affects the inside lining of the chest cavity. ALIMTA is given with , another anticancer medicine (chemotherapy), when surgery is not an option.

Additional Information:

• Delivery Time: ready

Product Details:

Alimta 500mg

Alimta Supplier

Alimta Lilly

Additional Information:

• Pay Mode Terms: D/P,D/A,Other
• Port of Dispatch: Ahmedabad
• Delivery Time: Standard Time
• Packaging Details: 1Vial x 500mg 1Vial x 100mg